Intra-Cellular Therapies, Inc. (ITCI)
Market Cap | 5.88B |
Revenue (ttm) | 310.62M |
Net Income (ttm) | -228.19M |
Shares Out | 95.93M |
EPS (ttm) | -2.41 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 661,392 |
Open | 60.09 |
Previous Close | 59.53 |
Day's Range | 59.03 - 61.66 |
52-Week Range | 42.01 - 66.56 |
Beta | 1.14 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | May 4, 2023 |
About ITCI
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as s... [Read more]
Full Company ProfileFinancial Performance
In 2022, ITCI's revenue was $250.31 million, an increase of 198.69% compared to the previous year's $83.80 million. Losses were -$256.26 million, -9.81% less than in 2021.
Financial StatementsNews

Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervo...

Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
Q1 2023 total revenues of $95.3 million, compared to $35.0 million in the same period in 2022 CAPLYTA Q1 2023 net product sales were $94.7 million, compared to $34.8 million for the same period in 202...

Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervo...

Intra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and Webcast
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ner...

Intra-Cellular Therapies to Present at the 22nd Annual Needham Virtual Healthcare Conference
NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ner...

Intra-Cellular's stock jumps on new data for depression drug
Shares of Intra-Cellular Therapies Inc. ITCI, +2.46% jumped about 15% in premarket trading on Tuesday after the company said its experimental treatment for major depressive disorder met the primary en...

Intra-Cellular Therapies Announces Positive Topline Results from Study 403 Evaluating Lumateperone as Monotherapy in Patients with Major Depressive Disorder with Mixed Features and Bipolar Depression with Mixed Features
Lumateperone 42mg was statistically significant on the primary endpoint of symptom reduction on the Montgomery Asberg Depression Rating Scale (MADRS) for each patient population including:

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
Full year 2022 total revenues of $250.3 million, compared to $83.8 million in 2021

Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

Intra-Cellular Therapies to Present at the SVB Securities Global Biopharma Conference
NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

Intra-Cellular Therapies to Present at the 41st Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

Intra-Cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
CAPLYTA net product revenues for the third quarter 2022 were $71.9 million, compared to $21.6 million for the same period in 2021, representing a 233% increase over the same period in 2021 and a 30% i...

Intra-Cellular Therapies to Host Third Quarter 2022 Financial Results Conference Call and Webcast
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

Intra-Cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Total revenues for the second quarter 2022 were $55.6 million, compared to $20.0 million for the same period in 2021, representing a 178% increase

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Intra-Cellular Therapies, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK , Aug. 4, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...

Intra-Cellular Therapies to Host Second Quarter 2022 Financial Results Conference Call and Webcast
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Intra-Cellular Therapies, Inc. with Losses to Contact the Firm
Los Angeles, California--(Newsfile Corp. - June 24, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intr...

Robust Uptake Of Antipsychotic Drug Boosts Intra-Cellular's Q1 Earnings
Intra-Cellular Therapies Inc's (NASDAQ: ITCI) Q1 revenues reached $35.0 million, compared to $15.9 million a year ago, beating the consensus of $33.65 million. Net product revenues of Caplyta were $34...

Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
First quarter 2022 results reflect strong CAPLYTA ® (lumateperone) launch in bipolar depression

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
Received FDA approval for CAPLYTA ® (lumateperone) for the treatment of bipolar depression in adults.

Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast
NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

Intra-Cellular Therapies to Present at the 11th Annual SVB Leerink Global Healthcare Conference
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

Intra-Cellular Therapies Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

Intra-Cellular Therapies Prices Public Offering of Common Stock
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...